Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cancer Historically agents given systemically – Agents that kill rapidly dividing cells Find therapeutic dose  Kills tumor cells w/o killing patient –

Published byEvan Shepherd Modified over 9 years ago

Similar presentations

Presentation on theme: "Cancer Historically agents given systemically – Agents that kill rapidly dividing cells Find therapeutic dose  Kills tumor cells w/o killing patient –"— Presentation transcript:

1 Cancer Historically agents given systemically – Agents that kill rapidly dividing cells Find therapeutic dose  Kills tumor cells w/o killing patient – Lots of side effects Localized/targeted delivery is the holy grail – Nanomedicine!! – Also protection from degradation and increased solubility

2

3 Nanoparticles – drug throughout Nanocapsules – drug w/in coating PEGylation – makes stealthy Ligand – binds to cell receptor for targeting

4 Tumor Vasculature Irregularly shaped, big, and leaky Lack of lymph drainage High vessel density

5 Passive Targeting  EPR Small drugs enter tumor and leave Particles enter and stay – Long circulation time key

6 Active Targeting EPR + something that binds tumor cells specifically

7 Targeting  Interfere with signaling when bind (targeting ligand and drug)  Ab tethered to drug  Ligand + drug  depends upon over-expression of surface molecules by tumor cells

8 Paige

9 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Paige

10 Daruwalla, Cancer Science, 2010; 101; 1866-1874 MoCR IC 50 =1.2  M MCF-7 IC 50 =0.8  M HT-29 IC 50 =0.85  M DLD-1 IC 50 =0.8  M Paige

11 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Shrinidhi

12 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Shrinidhi

13 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Shrinidhi

14 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Anna

15 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Anna

16 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Anna

17 Daruwalla, Cancer Science, 2010; 101; 1866-1874 Felix

18 Kevin

19 Lehtinen, PLOS One, 2012; 7(7); e41410- Kevin

20 Lehtinen, PLOS One, 2012; 7(7); e41410- Inseong

21 Lehtinen, PLOS One, 2012; 7(7); e41410- Inseong

22 Lehtinen, PLOS One, 2012; 7(7); e41410- Maura background non-targeted pre-targeted direct target

23 Lehtinen, PLOS One, 2012; 7(7); e41410 Maura

24 Lehtinen, PLOS One, 2012; 7(7); e41410- Michael

Download ppt "Cancer Historically agents given systemically – Agents that kill rapidly dividing cells Find therapeutic dose  Kills tumor cells w/o killing patient –"

Similar presentations

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Cell membranes are composed of two phospholipid layers.

Cell membranes are composed of two phospholipid layers.
 Since the cell cycle is known, now we must ask what controls it  Noted that healthy cells in contact will not divide ◦ Essentially, this is how our.

 Since the cell cycle is known, now we must ask what controls it  Noted that healthy cells in contact will not divide ◦ Essentially, this is how our.
CHAPTER 10 Basic Biopharmaceutics

CHAPTER 10 Basic Biopharmaceutics
Cell Transport The movement of molecules can be either passive (no energy) or active (needs energy) depending upon the membrane structure and concentration.

Cell Transport The movement of molecules can be either passive (no energy) or active (needs energy) depending upon the membrane structure and concentration.
Cancer Imaging Topics in Bioengineering. The present and future role of cancer imaging Fass L. (2008) Mol Oncol. Figures 1 & 2.

Cancer Imaging Topics in Bioengineering. The present and future role of cancer imaging Fass L. (2008) Mol Oncol. Figures 1 & 2.
Nanomedicines for diagnosis and therapy. Nanomedicines.

Nanomedicines for diagnosis and therapy. Nanomedicines.
Dental Microbiology #211 IMMUNOLOGY 2006 Lecture 2 The Lymphocytes.

Dental Microbiology #211 IMMUNOLOGY 2006 Lecture 2 The Lymphocytes.
Delivery Of Proteins: Target Site-specific Delivery By The Parenteral Route Saeb Aliwaini1.

Delivery Of Proteins: Target Site-specific Delivery By The Parenteral Route Saeb Aliwaini1.
Nanotechnology and medicine Dina Khater – 3 April 2011 - SFC.

Nanotechnology and medicine Dina Khater – 3 April SFC.
 Since the cell cycle is known, now we must ask what controls it  Noted that healthy cells in contact will not divide ◦ Essentially, this is how our.

 Since the cell cycle is known, now we must ask what controls it  Noted that healthy cells in contact will not divide ◦ Essentially, this is how our.
Diabetes: Glucose Monitoring

Diabetes: Glucose Monitoring
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 2 Drug Action and Handling.

Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 2 Drug Action and Handling.
 Cell cycle is known, so now we ask what controls it  We have observed many factors that influence a cell’s ability to move forward in the cycle ◦ Kinetochores.

 Cell cycle is known, so now we ask what controls it  We have observed many factors that influence a cell’s ability to move forward in the cycle ◦ Kinetochores.
.  Based on particle size and surface charge characterization studies, both nanoparticles have successfully been synthesized.  Successful conjugation.

.  Based on particle size and surface charge characterization studies, both nanoparticles have successfully been synthesized.  Successful conjugation.
Keith Johnston Research Group Nanotechnology/Colloid Science CPE 5.414 512-471-4617 Biomedical and Pharmaceutical.

Keith Johnston Research Group Nanotechnology/Colloid Science CPE Biomedical and Pharmaceutical.
Antibody and prodrug therapy of cancer

Antibody and prodrug therapy of cancer
SCALABLE PRODUCTION OF POLYMERIC NANOPARTICLES YING LIU ASSISTANT PROFESSOR DEPARTMENT OF CHEMICAL ENGINEERING DEPARTMENT OF BIOPHARMACEUTICAL SCIENCES.

SCALABLE PRODUCTION OF POLYMERIC NANOPARTICLES YING LIU ASSISTANT PROFESSOR DEPARTMENT OF CHEMICAL ENGINEERING DEPARTMENT OF BIOPHARMACEUTICAL SCIENCES.

Similar presentations

Ads by Google